Biomimetic Therapeutics, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Biomimetic Therapeutics, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Biomimetic Therapeutics, Inc.. The Group's principal activity is to develop and commercialize bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. It received US marketing approval for its first product for bone regeneration in periodontal defects following completion of human clinical trials. The Group's first product GEM 21S is a fully synthetic regeneration system that combines a tissue growth factor, recombinant human Platelet-Derived Growth Factor, with a synthetic bone matrix, beta-tricalcium phosphate. Its lead product and product candidates combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. The Group operates throughout United States of America.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report